Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-09-30

Clinical Trial Update: A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) used four times daily in adults and children 4 yea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) (budesonide and albuterol)

Snippet

Sponsor: Bond Avillion 2 Development LP | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2022-09-30